RxSight, Inc. reiterating earnings guidance for the full year 2024, for the year, the company expects revenue guidance range of $128.0 million to $135.0 million, representing implied growth of 44% to 52% compared to 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.29 USD | +6.78% | +5.98% | +59.45% |
05-13 | RxSight Raises $115 Million From Public Offering of Shares | MT |
05-07 | Wells Fargo Adjusts RxSight Price Target to $68 From $61, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.45% | 2.51B | |
-4.98% | 182B | |
+2.84% | 112B | |
-2.68% | 68.58B | |
+4.53% | 51.58B | |
+8.00% | 44.24B | |
+9.45% | 43.65B | |
+25.30% | 32.46B | |
+20.94% | 25.99B | |
-0.17% | 25.61B |
- Stock Market
- Equities
- RXST Stock
- News RxSight, Inc.
- Rxsight, Inc. Reiterates Earnings Guidance for the Full Year 2024